Citi Starts PRA Health Sciences (PRAH) at Neutral

UPDATE: Credit Suisse Starts PRA Health Sciences (PRAH) at Outperform

(Updated - December 8, 2014 10:30 AM EST)

Credit Suisse initiated coverage on PRA Health Sciences (NASDAQ: PRAH) with an Outperform rating and a price target of $27.00.

"PRAH is a global clinical contract research organization (CRO) that provides outsourced services to support all stages of the clinical... More

UBS Starts PRA Health Sciences (PRAH) at Buy

UBS initiated coverage on PRA Health Sciences (NASDAQ: PRAH) with a Buy rating and a price target of $28.00.

For an analyst ratings summary and ratings history on PRA Health Sciences click here. For more ratings news on PRA Health Sciences click here.

Shares of PRA Health Sciences closed at $22.06 yesterday.

Baird Starts PRA Health Sciences (PRAH) at Outperform

Baird initiated coverage on PRA Health Sciences (NASDAQ: PRAH) with an Outperform rating and a price target of $28.00.

For an analyst ratings summary and ratings history on PRA Health Sciences click here. For more ratings news on PRA Health Sciences click here.

Shares of PRA Health Sciences closed at $22.06 yesterday.

Wells Fargo Starts PRA Health Sciences (PRAH) at Outperform

Wells Fargo initiated coverage on PRA Health Sciences (NASDAQ: PRAH) with an Outperform rating and a price target of $25-$26.

For an analyst ratings summary and ratings history on PRA Health Sciences... More

Jefferies Starts PRA Health Sciences (PRAH) at Buy

Jefferies initiates coverage on PRA Health Sciences (NASDAQ: PRAH) with a Buy rating and a price target of $27.00.

Analyst David Windley comments, "PRA's project-based and functional service solutions combined with the additive RPS client base offer significant cross-selling opportunities and the potential for... More